occurrence of tumors with a multidrug resistance (MDR). Furthermore, the relation between overexpression of P-glycoprotein (P-gp) and resistant cancers has been well established. In this study, novel 2-aminobenzofuran derivatives were synthesized and tested for their ability to modulate P-gp mediated multidrug resistance (MDR) in vitro. The most potent compound, 43, increased P-gp inhibitory activity at 5 μM
用化疗药物治疗癌症患者通常与多药耐药性(MDR)肿瘤的发生有关。此外,P-糖蛋白(P-gp)的过表达与耐药性癌症之间的关系已经得到很好的建立。在这项研究中,合成了新型的2-
氨基
苯并呋喃衍
生物,并测试了它们在体外调节P-gp介导的多药耐药性(MDR)的能力。最有效的化合物43在5μM时提高P-gp抑制活性11.12倍,比
维拉帕米强3.6倍。此外,在2.5μM浓度下,43可使Flp-In™-293 / MDR细胞对
长春新碱,
紫杉醇和
阿霉素的敏感性分别提高17.95倍,13.68倍和26.43倍。43在2.5μM的浓度下,还可使耐药癌
细胞系KBvin对
长春新碱,
紫杉醇和
阿霉素的敏感性分别提高246.43倍,38.72倍和5.16倍。总之,在这项研究中强调了开发有效的P-gp
抑制剂的重要方面,为进一步优化P-gp
抑制剂的结构提供了起点。